Lexeo Therapeutics, Inc. (LXEO), a company specializing in genetic medicine, has announced the immediate appointment of Kyle Rasbach as its Chief Financial Officer. Prior to joining Lexeo, Rasbach held the position of Chief Business Officer at Zentalis Pharmaceuticals. As of Wednesday, Lexeo's shares fell by 8.62%, closing at $6.36 on the Nasdaq.
The material has been provided by InstaForex Company - www.instaforex.com
The material has been provided by InstaForex Company - www.instaforex.com